louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00426699: Urinary Excretion of Enteroviruses From Children With a Presumed Enteroviral Infection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Enterovirus Infections
Keywords: enterovirus
meningitis
sepsis
myocarditis
kidney
urine
glomerulonephritis
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor class: OTHER
First posted: 2007-01-25
Enrollment: 82
Sex: ALL
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: children age 0-16

Brief summary: Enteroviruses can infect most human organ systems, especially the heart, nervous system and pancreas. Whether Enteroviruses can also affect the kidneys is not known yet. Therefore we will analyze urine of children with a suspected enteroviral infection for enteroviruses and signs of kidney infection.

Detailed description: Enteroviruses have been shown to cause mesangioproliferation and glomerulonephritis in mice (especially coxsackievirus B4). In some cases, large amounts of IgA are deposited in the mesangium, resembling human IgA-nephropathy. In humans, case reports indicate the propensity of certain enteroviruses to cause kidney infections.

Our project aims to analyze urine of children with suspected enteroviral infections (e.g. meningitis, myocarditis, sepsis of the newborn etc.) to identify cases suspicious of concomitant enteroviral kidney affection. To achieve this aim, enterovirus-PCRs will be performed and microhematuria searched for.

Eligibility criteria: Inclusion Criteria:

* children, suspected of suffering from an enteroviral infection

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bern
country: Switzerland
facility: Dept. Nephrology & Hypertension, Univ. Hospital Bern
Study officials:
affiliation: University of Bern
name: Andreas Pasch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00000299: Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2
Official title: Rapid Opiate Detoxification & Naltrexone Induction Using Bup.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Opioid-Related Disorders
Keywords: Opioid-Related Disorders
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 1999-09-21
Enrollment: 12
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to develop a clinical protocol to detoxify patients from opiates to naltrexone using buprenorphine and to develop pilot data for a grant application for a controlled study of the efficacy of the new clinical protocol for outpatients.


Eligibility criteria: Inclusion Criteria:

Males/Females, ages 21-50. Opiate dependence according to DSM-IV criteria. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent.

Exclusion Criteria:

psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependent on etoh or benzodiazepines or other sedative-hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.

Primary outcomes:
measure: Opiate craving
timeFrame: 10 test days
measure: Opiate withdrawal symptoms
timeFrame: 10 test days
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Friends Research Institute
state: California
Study officials:
affiliation: Friends Research Institute, Inc.
name: Walter Ling, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01339299: Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)
Official title: The Endocrine Efficacy of Either Recombinant Luteinizing Hormone (r-LH) or Low Dose Recombinant Human Chorionic Gonadotropin (r-hCG) Supplementation for Recombinant Follicle Stimulating Hormone (r-FSH) Stimulation in Normogonadotrophic Women Undergoing in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Therapy Following a Long-term Gonadotropin Releasing Hormone (GnRH) Agonist Down Regulation Protocol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Controlled Ovarian Stimulation
Infertility
Keywords: COS
ART
Infertility
Lead sponsor: Regionshospitalet Viborg, Skive
Sponsor class: OTHER
First posted: 2011-04-20
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The study is a prospective, randomised, controlled, and non-blinded multi-center pilot study to evaluate endocrine efficacy of recombinant luteinizing hormone versus recombinant human chorionic gonadotropin administered during controlled ovarian stimulation for IVF/ICSI in normogonadotrophic women.


Eligibility criteria: Inclusion Criteria:

* Women who plan to undergo IVF or ICSI treatment
* Woman's age \> 18 years but ≤ 35 years
* Regular menstrual cycle (25-34 days)
* BMI 18 to 30 inclusive
* Signed patient information and informed consent forms

Exclusion Criteria:

* PCOS
* More than 2 prior IVF/ICSI attempts
* Diabetes mellitus, epilepsy, lever-, kidney-, heart- and metabolism disorders, according to the Investigator's assessment.

Primary outcomes:
measure: The Oestradiol Concentration on the Day of Ovulation Induction
timeFrame: treatment day 10 to 14
Secondary outcomes:
Other outcomes:
Locations:
city: Skive
country: Denmark
facility: Fertility Clinic Skive regional Hospital
Study officials:
References:
Clinical trial NCT05899699: Effect of New Topical Preparation for Treatment of Acne Vulgaris
Official title: Potential Combination Topical Therapy of Acne Vulgaris: a Randomized Controlled Trial Comparing Efficacy of DAP/FLU Micro-emulsion vs. Standard Therapy of Adapalene.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Acne Vulgaris
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2023-06-12
Enrollment: 20
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators propose a randomized, double-blind control trial study to evaluate the efficacy and safety of the optimized topical combination ME of the investigated drugs in the treatment of acne vulgaris containing DAP-FLU in comparison with standard therapy of Adapalene at Mansoura University Dermatology and Andrology Outpatient Clinic.


Eligibility criteria: Inclusion Criteria:

1. Male and females age 12 or older
2. Clinical diagnosis of mild to moderate facial acne vulgaris defined as:

   1. ≥ 5 inflammatory lesions, and;
   2. ≥ 10 non-inflammatory lesions, and;
   3. IGA 2-3
3. Willing to refrain from using any treatments, other than the investigational product, for acne present on the face. This includes the use of antibiotics for the treatment of acne.
4. Willing and able to provide informed consent and to comply with the study protocol.

Exclusion Criteria:

1. Women were excluded if they were pregnant, nursing, or planning a pregnancy as were men with facial hair that would interfere with the assessments.
2. Continuous or planned use of tanning booths or excessive sun exposure, in the opinion of the Investigator.
3. Treatment with systemic corticosteroids within 28 days prior to baseline.
4. Two or more active nodular lesions.
5. Use of androgen receptor blockers (such as spironolactone or flutamide) in the 7 days prior to randomization.

Primary outcomes:
measure: Michaelson's acne severity index (ASI)
timeFrame: 8 Weeks
measure: Safety assessment by the recording of patient-reported adverse events
timeFrame: 8 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Amgad El-Sayed Salem
Study officials:
affiliation: Mansoura University
name: Amgad El-Sayed Salem
role: STUDY_DIRECTOR
affiliation: Mansoura University
name: Elham A. Mohamed
role: STUDY_DIRECTOR
affiliation: Mansoura University
name: Noha M. Saleh
role: STUDY_DIRECTOR
affiliation: Mansoura University
name: Marwa Z. Mubarak
role: STUDY_DIRECTOR
affiliation: Mansoura University
name: Galal M. Abdelghania
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05184699: The Effect of Dietary Intervention on Endothelial Glycocalyx in Psoriasis
Official title: The Effect of Dietary Intervention on Endothelial Glycocalyx Integrity and Microvascular Perfusion in Patients With Psoriatic Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Psoriasis
Keywords: psoriasis
endothelial glycocalyx
arterial stiffness
coronary microcirculation
left ventricular myocardial deformation
Lead sponsor: University of Athens
Sponsor class: OTHER
First posted: 2022-01-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Sixty patients with psoriatic disease will be randomized to receive food supplement Endocalyx (n=30) or placebo (n=30) for 4 consecutive months.
Primary purpose: PREVENTION

Brief summary: The food supplement Endocalyx is considered to support the endothelial glycocalyx integrity by supplying sulfated polysaccharides, anti-oxidant enzymes and additional substrates for glycocalyx synthesis. The investigators will study the effect of Endocalyx on endothelial, vascular and left ventricular myocardial function in patients with psoriatic disease.

Detailed description: Sixty patients with psoriatic disease, who are referred to the outpatient psoriasis clinic of the Attikon University Hospital, will be randomized to receive food supplement Endocalyx (4 capsules per day) (n=30) or placebo (n=30) for 4 consecutive months.

Eligibility criteria: Inclusion Criteria:

* Caucasian patients with psoriatic disease (plaque-type psoriasis or psoriatic arthritis)
* Body mass index ≥18.5 Kg/m2
* If female, patients must be non-pregnant and non-breastfeeding

Exclusion Criteria:

* History of acute coronary syndrome. Coronary artery disease will be excluded by a clinical history, examination and electrocardiogram.
* Moderate or severe valve disease
* Primary cardiomyopathies
* Chronic obstructive pulmonary disease
* Asthma
* Chronic kidney disease
* Liver failure
* Malignancies

Primary outcomes:
measure: Endocalyx effects on endothelial glycocalyx thickness
timeFrame: four months
Secondary outcomes:
measure: Endocalyx effects on arterial stiffness
timeFrame: four months
measure: Endocalyx effects on coronary microcirculation
timeFrame: four months
measure: Endocalyx effects on left ventricular myocardial function
timeFrame: four months
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Attikon University Hospital
state: Attiki
Study officials:
affiliation: 2nd Cardiology Department, National and Kapodistrian University of Athens
name: Ignatios Ikonomidis, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01629199: Efficacy and Safety of rhEGF in Diabetic Foot Ulcer Patients With Uncontrolled Diabetic Mellitus
Official title: The Clinical Trial for Evaluation of Efficacy and Safety of rhEGF(Recombinant Human Epidermal Growth Factor) in Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Sponsor class: INDUSTRY
First posted: 2012-06-27
Enrollment: 176
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical trial is to evaluate the safety and efficacy of rhEGF (recombinant human Epidermal Growth Factor) in diabetic foot ulcer patients with uncontrolled diabetes mellitus.



Primary outcomes:
measure: At 12 weeks, wound closure rate of diabetic foot ulcers
timeFrame: 12 weeks from the start day of treatment (But, the study can be finished before 12 weeks)
Secondary outcomes:
measure: Time to reach complete wound closure
timeFrame: 12weeks
measure: average size reduction of diabetic ulcer
timeFrame: 12 week
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: College of Medicine, Yonsei University
Study officials:
References:
Clinical trial NCT03154242: Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer
Official title: Effect of Genetic Polymorphisms on Clinical Outcome of Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: non small cell lung cancer
NSCLC
Platinum
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2017-05-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: clinical oncology department at Al Demerdash hospital

Brief summary: This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients


Eligibility criteria: Inclusion Criteria:

1. Newly diagnosed with immunohistochemically and pathologically confirmed non-small cell lung cancer (NSCLC).
2. Eastern Cooperative Oncology Group performance status (ECOG PS) = 0-2.
3. Chemotherapy naïve.
4. Age \>18 years.
5. Adequate bone marrow reserve

Exclusion Criteria:

1. Presence of Central nervous system(CNS) metastases.
2. Inadequate liver function
3. Inadequate renal function
4. Serious comorbid systemic disorder incompatible with the study.
5. Pregnancy

Primary outcomes:
measure: Progression-free survival (PFS)
timeFrame: From the date of starting the chemotherapy until the date of documented disease progression or date of death from any cause assessed up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al Demerdash Hospital
Study officials:
affiliation: Ain Shams University
name: Esraa S Abdalkhalek
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03566342: Optimal Regimen of Patient-controlled Epidural Analgesia in Laboring Patients
Official title: Optimal Regimen of Patient-controlled Epidural Analgesia in Laboring Patients Receiving Combined Spinal and Epidural Analgesia (CSE)
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: LABOR PAIN
Lead sponsor: Maimonides Medical Center
Sponsor class: OTHER
First posted: 2018-06-25
Enrollment: 145
Sex: FEMALE
Minimum age (years): 16
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Laboring women receiving combined spinal epidural analgesia for pain relief

Brief summary: To test the efficacy of different recipes of epidural infusions used for providing pain relief during labor in parturients.

Detailed description: In this prospective trial, the investigators would like to examine the efficacy of several different PCEA protocols in 250 parturients who receive CSE for labor pain. Any patient with failed epidural, delivery within 2 hours of epidural insertion, or Cesarean section will be excluded from the study. Each patient will be assigned to one of five groups (A - E), depending on the day of admission for delivery, excluding Friday and Saturday (observed religious holidays). Each group will have 50 patients.

Eligibility criteria: Inclusion Criteria:

Parturients receiving Combined Spinal epidural analgesia for labor pain relief.

Exclusion Criteria:

Any patient with failed epidural, delivery within 2 hours of epidural insertion, or Cesarean section will be excluded from the study.

Primary outcomes:
measure: Pain scores
timeFrame: 24 to 48 hours.
Secondary outcomes:
measure: Number of boluses
timeFrame: 24 to 48 hours
measure: Amount of medication used
timeFrame: 24 to 48 hours
measure: Motor block
timeFrame: 24 to 48 hours.
measure: Height of the patient
timeFrame: At recruitment of the patient in to the study
measure: Weight of the patient
timeFrame: At recruitment of the patient in to the study
measure: Overall patient satisfaction
timeFrame: 24 to 48 hours
measure: Mode of delivery
timeFrame: 24 to 48 hours
Other outcomes:
Locations:
Study officials:
affiliation: MAIMONIDES MEDICAL CENTER, 4802, 10TH AVENUE, BROOKLYN, NY-11219
name: KALPANA TYAGARAJ
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00354042: Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects
Official title: A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 4 Period Crossover Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of GW597901X in Asthmatic Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Asthma
Keywords: GW597901X
Asthma
Crossover
dose ascending
repeat dose
inhaled
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2006-07-20
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study is designed to look at the safety aspects and effects of repeat inhaled doses of GW597901X in asthmatics to develop this drug for its use in asthma and Chronic Obstructive Pulmonary Disease(COPD).


Eligibility criteria: Inclusion criteria:

* Subjects with mild to moderate stable asthma but no other lung problems.
* Male subjects or female subjects who are not able to get pregnant (e.g. post-menopausal or surgically sterile).
* Non-Smokers.
* Subjects who show a measurable improvement in the function of their lungs after a single dose of salbutamol.

Exclusion criteria:

* Any significant illness.
* Subjects with heart problems.
* Subjects who have a cold or chest infection 2-4 weeks prior to the study or have life-threatening asthma.
* Subjects who take medication for their asthma, or other conditions, not compatible with this study.
* Subjects who are over sensitive to salbutamol or to ipratropium.

Primary outcomes:
measure: Safety Tolerability including blood test results, effects on the heart, pulse rate and blood pressure, and any side effects.
Secondary outcomes:
measure: Effects on the lungs at 12 and 24 hours Effects on the heart, blood pressure and heart rate at 8 hours Effects on blood tests over 4 hours and 8 hours Reduction of rescue medication.
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials, MD, MSc, FPPM
role: STUDY_DIRECTOR
References:
Clinical trial NCT03340142: VIVO™ Accuracy Study
Official title: VIVO™ Accuracy Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Premature Ventricular Contraction
Ventricular Tachycardia
Lead sponsor: Catheter Precision. Inc.
Sponsor class: INDUSTRY
First posted: 2017-11-13
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: A multi-center study designed to assess the accuracy of VIVO™ in determining the location of a PVC/VT foci in comparison to an electroanatomical mapping system.

Detailed description: The VIVO accuracy study will assess the accuracy of locating a PVC/VT foci by pacing known anatomical locations and comparing the VIVO outcome to that of the Carto system (Biosense-Webster).

Eligibility criteria: Inclusion Criteria:

* Subjects who are at least 18 years or older
* Subjects who are scheduled for PVC/VT ablation procedure with structurally normal hearts and less than 10% scar.
* Subjects who have signed an IRB/EC approved Informed Consent Form and applicable subject privacy protection authorization per local law
* Subjects will be selected without regard to gender or age (unless precluded by local regulatory requirements)

Exclusion Criteria:

* Subjects who are contraindicated for CT or MRI (must be able to get one)
* Subject whose MRI or CT scan does not comply with the requirements of this protocol
* Subjects who are contraindicated for an electrophysiology procedure and/or fluoroscopy:
* INR \> 3
* Active infection
* Pregnancy: Females of childbearing potential with a positive pregnancy test.
* Existing mechanical heart valve

Primary outcomes:
measure: Accuracy of correctly identifying PVC or VT origin
timeFrame: 1 Day
Secondary outcomes:
measure: Accuracy of correctly identifying known pacing sites
timeFrame: 1 Day
measure: Number of adverse events
timeFrame: 1 Day
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
city: Baltimore
country: United States
facility: Johns Hopkins Unveristy
state: Maryland
city: Charleston
country: United States
facility: Medical Unversity of South Carolina
state: South Carolina
Study officials:
affiliation: Catheter Precision. Inc.
name: Missiaen Huck
role: STUDY_DIRECTOR
References:
Clinical trial NCT01187342: Post Stroke Psychological Distress
Official title: Depression and Posttraumatic Stress Disorder in Stroke Patients: an Observational Study of Neuro-psychiatric, Cognitive, and MR-Changes Over Time After Stroke
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stroke
Keywords: Stroke
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: German Federal Ministry of Education and Research
First posted: 2010-08-24
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with acute ischemic stroke in MCA/AchA territory within 48 hours of onset

Brief summary: Neuro-psychological, cognitive and biochemical assessment matched with MR-Imaging in acute and chronic poststroke conditions.

Detailed description: The study design relates to affective symptomatology, particularly poststroke depression and posttraumatic stress symptoms as well as to cognitive decline due to stress-related hypercortisolemia in the early phase after stroke. Extended MRI studies including a functional connectivity (fc-MRI) paradigm have been incorporated to study on subacute midbrain neurodegeneration as a possible morphological correlate of functional and clinical findings.

Eligibility criteria: Inclusion Criteria:

* Stroke in MCA/AchA territory of striato-capsular (at least 125mm³) or non-striatal (10-100cm³) involvement
* MR-imaging can be conducted 24-48 hours of onset
* preserved communication skills

Exclusion Criteria:

* Patients with psychiatric conditions or medication in the last 4 weeks
* severe medical conditions
* limited prognosis

Primary outcomes:
measure: occurence of depression (GDS, SKID)
timeFrame: 90 days
Secondary outcomes:
measure: change in saliva cortisol
timeFrame: 90days
measure: change in serumcholine
timeFrame: 90days
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité, Campus Benjamin Franklin, Dep. of Neurology
Study officials:
affiliation: Center for Stroke Research Berlin
name: Matthias Endres, MD
role: STUDY_DIRECTOR
References: